Expert Interview
Discussing avutometinib combo and GFH375 from Verastem and daraxonrasib from Revolution Medicines prior to ASCO
Ticker(s): RVMD, VSTMInstitution: John Hopkins
- Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center.
- Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options
- Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer.
Roughly how many pancreatic cancer patients do you manage?
Added By: wilson_adminHow high is the bar for novel therapies in PDAC?
Added By: wilson_adminWhat is your impression of the side effect profile and efficacy seen in avutometinib from Verastem and daroxonrasib from Revolution?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
